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Summary
Although chronic infection with cytomegalovirus (CMV) is known
to drive T lymphocytes toward a senescent phenotype, it remains
controversial whether and how CMV can cause coronary heart
disease (CHD). To explore whether CMV seropositivity or T-cell
populations associated with immunosenescence were informa-
tive for adverse cardiovascular outcome in the very old, we
prospectively analyzed peripheral blood samples from 751 octo-
genarians (38% males) from the Newcastle 85+ study for their
power to predict survival during a 65-month follow-up (47.3%
survival rate). CMV-seropositive participants showed a higher
prevalence of CHD (37.7% vs. 26.7%, P = 0.030) compared to
CMV-seronegative participants together with lower CD4/CD8
ratio (1.7 vs. 4.1, P < 0.0001) and higher frequencies of senes-
cence-like CD4 memory cells (41.1% vs. 4.5%, P < 0.001) and
senescence-like CD8 memory cells (TEMRA, 28.1% vs. 6.7%,
P < 0.001). CMV seropositivity was also associated with increased
six-year cardiovascular mortality (HR 1.75 [1.09–2.82], P = 0.021)
or death from myocardial infarction and stroke (HR 1.89 [107–
3.36], P = 0.029). Gender-adjusted multivariate Cox regression
analysis revealed that low percentages of senescence-like CD4 T
cells (HR 0.48 [0.32–0.72], P < 0.001) and near-senescent (CD27
negative) CD8 T cells (HR 0.60 [0.41–0.88], P = 0.029) reduced the
risk of cardiovascular death. For senescence-like CD4, but not
near-senescent CD8 T cells, these associations remained robust
after additional adjustment for CMV status, comorbidities, and
inflammation markers. We conclude that CMV seropositivity is
linked to a higher incidence of CHD in octogenarians and that
senescence in both the CD4 and CD8 T-cell compartments is a
predictor of overall cardiovascular mortality as well as death from
myocardial infarction and stroke.
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Introduction
Human cytomegalovirus (CMV) is a ubiquitous herpes virus and shares a
high prevalence in developed countries (Crough & Khanna, 2009). A
growing body of evidence suggests an important role of CMV during
aging (Pawelec et al., 2009; Solana et al., 2012). Seropositivity for CMV
is one of the parameters in the immune risk profile (IRP), associated with
increased mortality in longitudinal studies in octo- and nonagenarians
(Nilsson et al., 2003). While the IRP was present in only 20% of the 85-
year-olds in the Swedish OCTO/NONA series, CMV seropositivity is
present in approx. 80–90% of octogenarians (Olsson et al., 2000; Wikby
et al., 2002; Nilsson et al., 2003). Phenotypical changes in the immune
system attributable to CMV are most visible in the T-cell compartment,
coinciding with clonal expansion and preferential expansion of
CD8+CD45RA+CD27 cytolytic T cells (Khan et al., 2002; Kuijpers et al.,
2003). CD8 T-cell responses in CMV-seropositive elderly are character-
ized by an accumulation of dysfunctional T cells with short telomeres and
low proliferation potential, often considered as replicative senescent
(Ouyang et al., 2003; Griffiths et al., 2013). Clinically, CMV has been
linked to an increased incidence of coronary heart disease (CHD) in a
number of studies (Ridker et al., 1998; Muhlestein et al., 2000; Sorlie
et al., 2000; Blankenberg et al., 2001; Simanek et al., 2009). It has been
proposed that CMV-driven cardiovascular mortality might be the main
cause for the observed increase in mortality in CMV-seropositive people
over the age of 65 years (Savva et al., 2013). We have shown previously
that in CMV-seropositive patients with CHD, the degree of telomere
erosion in CD8 cells correlates with deterioration of left ventricular
function, linking immunosenescence and cardiovascular disease (Spyri-
dopoulos et al., 2009; Hoffmann et al., 2015). In offspring of longevity
families, individuals do not show CMV-associated changes to their
immune signatures, suggesting a genetic component in the immune
response to CMV (Derhovanessian et al., 2010). The goal of our study
was to evaluate whether in octogenarians CMV seropositivity and T-cell
senescence are independent predictors of all-cause and especially
cardiovascular and CHD-mediated mortality.
We prospectively analyzed peripheral blood samples from 749
octogenarians aged 85 years, approx. 38.5% were male (Table 1). A
total of 85.6% of participants were seropositive for cytomegalovirus
(CMV). There were no differences between CMV-positive and CMV-
negative groups regarding gender, cardiovascular risk factors, and
prevalence of a wide range of age-related diseases, with the sole
exception of a higher prevalence of ischemic heart disease in CMV-
positive study participants (37.7% vs. 26.7%, P = 0.030, Table 1). CMV
seropositivity was associated with major changes in the T-cell repertoire
including a decreased CD4/CD8 cell ratio and increased frequencies of
CD4 and CD8 effector memory (TEMRA) cells showing a senescence-like
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phenotype characterized here by loss of CD27 and CD28 expression in
the CD4 subset and by loss of CD45RO and CD27 in CD8 T cells. These
surface marker combinations have been associated with low proliferative
potential, short telomeres, low telomerase activity, and high expression
of KLRG1, an inhibitor of AKT-mediated proliferation (Henson & Akbar,
2009), and are thus regarded as good markers of a senescence-like T-cell
phenotype. However, there were no differences in the levels of
inflammatory markers at basal levels or following leukocyte stimulation
by LPS (Table S1). Males and females differed in their CD4/CD8 ratios,
but not in the frequencies of senescent CD4 or CD8 cells or in the levels
of inflammation markers (Table S2).
We assessed the impact of CMV status and T-cell subset fractions on
all-cause mortality in octogenarians from the Newcastle 85+ study for
which complete data for all leukocyte parameters, CMV status, and
confounding factors (comorbidity, basal interleukin-6 and TNF-a) were
available (n = 594). In gender-adjusted log-rank analyses, neither CMV
status (P = 0.235) nor CD4/CD8 ratio (P = 0.184) was associated with
all-cause mortality, but frequencies of senescence-like CD4 memory cells
(CD4+CD45RO+CD27CD28) were weakly predictive of survival
(P = 0.042). Similarly, a Cox regression model with leukocyte subsets
entered singly and adjusting for gender revealed only a low percentage
of senescence-like CD4 memory cells to be significant predictors of long-
term mortality (HR 0.69 [0.52–0.92], P = 0.012), but this disappeared
after adjustment for CMV status (Table S3). We conclude that in our
octogenarian cohort, the impact of CMV on all-cause mortality was low
and mediated by CD4 T-cell senescence.
To address the association between CMV infection, T-cell senescence,
and cardiovascular morbidity and mortality, we first compared T-cell
parameters and inflammation markers between CMV-seropositive study
participants with (n = 180) and without (n = 306) CHD (Table S4).
Interestingly, percentages of T-cell subpopulations in the CD4 and CD8
were not associated with CHD prevalence. However, inflammation
markers were different: Basal TNF-a serum levels and leukocyte
interleukin-6 responses to LPS stimulation were higher in CMV-
seropositive patients with CHD (Table S4).
Finally, survival analyses were repeated for mortality by cardiovascular
causes only. There were 134 deaths from myocardial infarction (MI) or
stroke (I20-25 or I60-69) and 184 deaths from any cardiovascular disease
(I00-69). In gender-adjusted log-rank analyses, positive CMV status was
significantly associated with increased six-year cardiovascular mortality
(HR 1.75, 95% CI 1.09–2.82, P = 0.021) and increased death from MI
and stroke (HR 1.89, 95% CI 1.07–3.36, P = 0.029). However, these
associations were no longer significant in separate analyses for men and
women (Fig. 1A and D). The CD4/CD8 ratio was not associated with
cardiovascular mortality in our cohort (Table S5). A low percentage of
senescence-like CD4 T cells (CD4+CD45RO+CD27CD28) predicted
decreased cardiovascular mortality (HR 0.48 [0.32–0.72], P < 0.001,
adjusted for gender, Table S5), which was confirmed by separate analyses
in men and women (Fig. 1B and E). Moreover, a low percentage of
nonsenescent CD8memory T cells (CD3+CD8+CD45RO+CD27+) predicted
increased cardiovascular mortality (HR 1.78 [1.27–2.48], P = 0.001) in the
Cox regression model after adjusting for gender (Table S5). It is known
that during progression to immunosenescence CD8 cells lose the CD28
coreceptor first followed by CD27 loss (Koch et al., 2008), indicating that
the loss of CD27 in the CD8 population delineates a more senescent
phenotype. Indeed, CD8+CD27 T cells, even if they are still capable of
proliferation, show multiple characteristics of a senescent phenotype,
including telomere dysfunction and activation of p38 MAPK signaling
(Henson et al., 2009; van de Berg et al., 2010; Lanna et al., 2013). Even if
they retain long telomeres, CD8+CD27- T cells show activated DNA
damage responses, specifically persistent DNA damage response associ-
ated with dysfunctional telomeres, and mitochondrial dysfunction
(Fig. S1), two major characteristics of the senescent phenotype (Passos
et al., 2010; Jurk et al., 2014). Accordingly, a low ratio of near-senescent
(CD27) to nonsenescent (CD27+) CD8T cells also predicted decreased
cardiovascular mortality (HR 0.60 [0.41–0.88], P = 0.01, adjusted for
gender, Table S5) although these associations did not remain significant
in separate log-rank analyses for men and women (Fig. 1C and F).
Associations of both senescence-like CD4 cells and nonsenescent CD8
TCM cells with cardiovascular mortality remained significant after
adjustment for CMV status (Table S5); however, after further adjustment
for comorbidity, a lower number of senescence-like CD4 T cells were the
only parameter to remain indicative of a favorable outcome. This
remained so after further adjusting for all inflammation markers (HR
0.57 [0.34–0.94], P = 0.027). Likewise, a low number of senescence-like
CD4 T cells also predicted decreased risk of death from MI and stroke
specifically after adjusting for gender, CMV, disease count, and cytokines
(HR 0.62 [0.40–0.95], P = 0.027).
Earlier studies had shown the impact of an ‘immune risk phenotype’
(IRP), a simplified surrogate parameter for an aged immune system
(immunosenescence) associated with CMV infection and a low CD4/CD8
ratio, onmortality in octa- and nonagenarians (Wikby et al., 2002; Nilsson
et al., 2003). In our population, these parameters were not significant
predictors of all-cause mortality, but CMV (although not the Cd4/CD8
ratio) predicted cardiovascular mortality as well as death fromMI or stroke
in agreement with recent results (Savva et al., 2013). Our data specify the
Table 1 Patient characteristics (n = 749)
Parameter CMV (n = 108) CMV+ (n = 641) P
Male gender (%) 42.6 37.8 0.339†
BMI (median, IQR) 23.93
(21.65–26.21)
24.36
(21.58–27.33)
0.170‡
Smokers
Never (%) 32.4 36.2 0.902†
Current (%) 5.6 5.5
Former – Regular (%) 56.5 53.0
Former – Occasional (%) 5.6 5.3
Institutional housing (%) 4.6 8.9 0.137†
Diabetes (%) 14.8 13.4 0.695†
Hypertension (%) 51.9 58.0 0.230†
Total Cholesterol (median, IQR) 4.70
(4.00–5.60)
4.80
(4.00–5.70)
0.880‡
Cardiovascular disease (%) 51.4 54.0 0.614†
Any atherosclerotic disease (%) 44.4 49.0 0.382†
Coronary heart disease (%) 26.7 37.7 0.030†
Cerebrovascular disease (%) 23.1 19.8 0.425†
Peripheral vascular disease (%) 6.5 6.9 0.884†
Heart failure (%) 10.2 11.4 0.714†
Rheumatoid arthritis (%) 2.8 3.0 0.916†
Cancer, any (%) 27.8 23.9 0.382†
Cancer, any (Excluding B&S,
<5 years since diagnosis) (%)
9.3 6.1 0.217†
Anemia (WHO’s Guideline) (%) 34.7 31.2 0.548†
Renal Impairment - CKD-Epi (%) 23.1 24.3 0.793†
Follow-up (months, median (IQR)) 65.07
(43.06–71.38)
65.02
(34.04–71.28)
0.491‡
Survival (%) 49.1 47 0.684†
†Chi-square.
‡Mann–Whitney U-test.
P values <0.05 are indicated in bold.
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alterations caused by CMV infection in the lymphocyte compartment that
are driving adverse events as those related to cell senescence in the CD4
and CD8 T-cell compartments. Cell senescence, including immune cell
senescence, is associated with telomere dysfunction, MAP kinase activa-
tion and mitochondrial dysfunction (Henson et al., 2009; van de Berg
et al., 2010; Passos et al., 2010; Lanna et al., 2013; Jurk et al., 2014),
which in turn cause hyperactivation of NF-jB- andC/EBPb-driven secretion
of pro-inflammatory peptides (the so-called senescence-associated secre-
tory phenotype or SASP (Coppe et al., 2008)). Conversely, chronic
activation of inflammatory signaling can aggravate the senescent pheno-
type (Jurk et al., 2014) and thus contribute to vascular dysfunction and
CVD (Wang&Bennett, 2012). Thus, our data support a possible causal role
for immunosenescence in CHD and are well in accord with the idea of a
generalized chronic pro-inflammatory state as a risk factor for the disease.
This possible cell-based mechanistic link between CMV and CHD via
ongoing generation of highly pro-inflammatory T cells of senescent
phenotype could also explain differences in the progression of age-related
atherosclerosis between individuals.
Our study was limited as we could not exclude subclinical CHD in the
remaining CMV+ patients, nor was the diagnosis of CHD angiographically
confirmed. It should also be noted that some studies have doubted a role
for CMV in immunosenescence and aging-associated inflammation (Cicin-
Sain et al., 2011; Bartlett et al., 2012). However, one of themused a rhesus
macaque model of aging (Cicin-Sain et al., 2011), where old was defined
as up to 26 years, and probably not comparable with the age of our
octogenarians. The study by Bartlett took CMV seropositivity into consid-
eration, but not T-cell immunity specifically (Bartlett et al., 2012). Derho-
vassian and coworkers have shown that the response to CMV can be very
heterogeneous and that immunological control of the virus can contribute
to decreased mortality rate (Derhovanessian et al., 2010). Our results
suggest CMV seropositivity as a driver of T-cell senescence that at least in
the CD4 compartment independently predicts cardiovascular mortality.
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